Celldex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	35.73	28.87	28.36	34.81	29.43	39.14
Short-Term Investments	415.73	489.7	696.93	388.78	275.52	369.11
Cash & Short-Term Investments	451.46	518.57	725.28	423.6	304.95	408.25
Cash Growth	-32.95%	-28.50%	71.22%	38.91%	-25.30%	109.98%
Accounts Receivable	0.23	2.02	0.7	2.63	0.35	0.17
Other Current Assets	7.53	14.08	21.18	5.47	12.39	2.42
Total Current Assets	459.22	534.66	747.16	431.69	317.69	410.84
Net Property, Plant & Equipment	9.41	7.77	8.24	6.64	7.75	6.52
Other Intangible Assets	27.19	27.19	27.19	27.19	27.19	27.19
Other Long-Term Assets	15.43	13.36	9.75	0.11	0.1	0.1
Total Assets	511.25	582.98	792.34	465.63	352.74	444.65
Accounts Payable	10.36	1.18	3.27	3.49	3.34	1.23
Accrued Expenses	38.42	47.03	33.84	22.03	12.84	12
Current Portion of Long-Term Debt	1.23	1.23	0.94	3.99	0.99	1.55
Current Portion of Leases	1.47	1.55	1.45	1.61	1.45	1.75
Total Current Liabilities	51.47	50.99	39.5	31.13	18.61	16.53
Long-Term Leases	0.44	0.78	2.36	0.93	2.59	1.3
Other Long-Term Liabilities	3.11	4.04	3.47	4.4	5.33	7.35
Total Long-Term Liabilities	3.56	4.83	5.83	5.33	7.92	8.65
Total Liabilities	55.03	55.82	45.34	36.46	26.53	25.18
Common Stock	0.07	0.07	0.07	0.06	0.05	0.05
Additional Paid-in Capital	2,346	2,337	2,299	1,823	1,581	1,561
Accumulated Other Comprehensive Income	2.52	3.63	3.31	3.31	1.26	1.89
Retained Earnings	-1,893	-1,814	-1,555	-1,397	-1,256	-1,144
Shareholders' Equity	456.23	527.17	747.01	429.17	326.2	419.48
Total Liabilities & Equity	511.25	582.98	792.34	465.63	352.74	444.65
Total Debt	3.14	3.57	4.76	6.53	5.02	4.6
Net Cash (Debt)	448.32	515.01	720.53	417.07	299.93	403.65
Net Cash Growth	-12.95%	-28.52%	72.76%	39.06%	-25.70%	115.20%
Net Cash Per Share	6.75	7.75	11.19	8.61	6.40	9.42
Book Value	456.23	527.17	747.01	429.17	326.2	419.48
Book Value Per Share	6.86	7.94	11.60	8.86	6.96	9.78
Tangible Book Value	429.04	499.98	719.82	401.98	299.01	392.29
Tangible Book Value Per Share	6.45	7.53	11.18	8.30	6.38	9.15

SEC Filings: 10-K · 10-Q